| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
GHENT, Belgium—Following its very recent launch via a merger, new early-phase contract development and manufacturing organization (CDMO) Ardena has already increased its existing capacity with the recent acquisition of Analytical Biochemical Laboratory (ABL). As the company noted in announcing this, adding ABL to the Ardena Group lends bioanalytical and drug discovery services that complement the initial service offerings.
 
Ardena was launched this fall following the merger of Belgian company Pharmavize and Netherlands-based Crystallics. The new company will now offer particular expertise in bioavailability enhancement and modified drug release and takes a dossier-centric approach to drug development. In adding the capacity offered by ABL, Ardena increases its utility to customers in helping with early-stage drug development across all phases.
 
With the addition of ABL, the Ardena Group now employs 125 scientists and boasts three facilities in Europe: Amsterdam (the former Crystallics facility) and Assen (the former ABL facility) in the Netherlands, plus the company’s headquarters in Ghent, Belgium, that once housed Pharmavize.
 
Commenting on the announcement, Ardena CEO Harry Christiaens said: “Our focus is to help customers navigate the hurdles of drug development, and in order to do this effectively, we need to deliver a broad and integrated service offering spanning drug discovery, preclinical, CMC [chemistry, manufacturing and controls] and clinical services.”
 
Following the initial merger, Christiaens was excited for the expertise Ardena could offer. “Drug developers need clinical materials on time in order to generate valuable clinical data and reach their next milestone, yet many face formulation challenges or lack the in-house infrastructure or regulatory knowledge required. With product and dossier developed together, quality and regulatory compliance can be ensured from the start of a project. With drug developers under increasing time and cost pressures, [we can help] to streamline the drug’s progress to clinic and eventually to commercial production. Quite simply, our focus is to create strong formulations and regulatory-compliant drug products for clients planning early-phase clinical trials.”
 
In acquiring ABL, Ardena adds to their specialist capabilities, making them a drug discovery partner for companies of all sizes. Founded in 1969, ABL specializes in the analysis of endogenous (biomarkers) and exogenous compounds (drugs) in biological matrices derived from humans and animals. The company is active in all phases of drug development, including discovery, preclinical and clinical trials from Phases 1-4.
 
“The acquisition of ABL was a strategic decision to further our goal to become a one-source contract partner for early-phase development,” says Christiaens. “With ABL’s expertise, we can now support sponsors with bioanalytical and drug discovery services to help them reach important preclinical and clinical milestones. These specialist capabilities complement our existing services, which include solid-state chemistry, analytical and formulation development and early-phase clinical supply manufacturing.”
 
Ep Oosting, managing director of ABL, added: “ABL has grown significantly since I first joined the company more than 25 years ago, and it’s exciting to be part of the next stage in its evolution. We’re looking forward to combining our expertise with that of the Ardena team to be able to offer our customers a more diverse and complete range of preclinical and early-phase drug development services. Moreover, we will continue offering and even expand our standalone bioanalytical services for the pharmaceutical industry to assist customers that require a more specific service.”

About the Author

Related Topics

Published In

Volume 13 - Issue 12 | December 2017

December 2017

December 2017 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Reliable fluid biomarkers strategies for clinical neuroscience research

Reliable fluid biomarkers strategies for clinical neuroscience research

Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
A group of blue capsules is scattered on a bright yellow surface, with one capsule opened to reveal white powder inside.

Understanding drug impurities: types, sources, and analytical strategies

Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue